Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial - Llombart-Cussac A; Pérez-García JM; Bellet M; Dalenc F; Gil-Gil M; Ruiz-Borrego M; Gavila J; Schmid P; Zamora P; Wheatley D; Martínez-de Dueñas E; Amillano K; et al. (2025)